Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis.

TO THE EDITOR—We read with interest the article by Fisher and colleagues about use of the galactomannan index (GMI) in hematopoietic stem cell transplant (HSCT) recipients with invasive aspergillosis (IA) [1]. The authors reported that the serum GM level at the time of IA diagnosis was significantly associated with the risk of overall and respiratory mortality. In their cohort, GM testing was performed upon clinical suspicion of IA; at our center, GM screening has been used even before clinical suspicion. Briefly, patients are tested at least twice weekly during the first 100 days after transplant or later in case of graft versus host